230 related articles for article (PubMed ID: 21107739)
21. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma.
Lissett CA; Peacey SR; Laing I; Tetlow L; Davis JR; Shalet SM
Clin Endocrinol (Oxf); 1998 Nov; 49(5):653-7. PubMed ID: 10197082
[TBL] [Abstract][Full Text] [Related]
22. Age- and Sex-Specific Differences as Predictors of Surgical Remission Among Patients With Acromegaly.
Park SH; Ku CR; Moon JH; Kim EH; Kim SH; Lee EJ
J Clin Endocrinol Metab; 2018 Mar; 103(3):909-916. PubMed ID: 29272449
[TBL] [Abstract][Full Text] [Related]
23. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
Biermasz NR; van Dulken H; Roelfsema F
J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114
[TBL] [Abstract][Full Text] [Related]
24. Clinical features and therapeutic outcomes of patients with acromegaly: single-center experience.
Dusek T; Kastelan D; Melada A; Baretic M; Skoric Polovina T; Perkovic Z; Giljevic Z; Jelcic J; Paladino J; Aganovic I; Korsic M
J Endocrinol Invest; 2011 Dec; 34(11):e382-5. PubMed ID: 21750393
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Effects of Intracapsular Debulking and Adjuvant Somatostatin Analogs for Growth Hormone-Secreting Pituitary Macroadenoma: 10 Years of Experience in a Single Institute.
Shen SC; Shen CC; Pu TW; Cheng WY
World Neurosurg; 2019 Jun; 126():e41-e47. PubMed ID: 30716503
[TBL] [Abstract][Full Text] [Related]
26. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
Abbassioun K; Amirjamshidi M; Mehrazin A; Khalatbary I; Keynama M; Bokai H; Abdollahi M
Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
[TBL] [Abstract][Full Text] [Related]
27. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.
Sheaves R; Jenkins P; Blackburn P; Huneidi AH; Afshar F; Medbak S; Grossman AB; Besser GM; Wass JA
Clin Endocrinol (Oxf); 1996 Oct; 45(4):407-13. PubMed ID: 8959078
[TBL] [Abstract][Full Text] [Related]
28. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
29. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
[TBL] [Abstract][Full Text] [Related]
30. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
Kim EH; Oh MC; Lee EJ; Kim SH
Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F
Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
[TBL] [Abstract][Full Text] [Related]
32. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
33. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
34. Endocrinological outcomes following endoscopic and microscopic transsphenoidal surgery in 113 patients with acromegaly.
Sarkar S; Rajaratnam S; Chacko G; Chacko AG
Clin Neurol Neurosurg; 2014 Nov; 126():190-5. PubMed ID: 25278017
[TBL] [Abstract][Full Text] [Related]
35. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
36. Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.
De P; Rees DA; Davies N; John R; Neal J; Mills RG; Vafidis J; Davies JS; Scanlon MF
J Clin Endocrinol Metab; 2003 Aug; 88(8):3567-72. PubMed ID: 12915637
[TBL] [Abstract][Full Text] [Related]
37. Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study.
Coopmans EC; Postma MR; Wolters TLC; van Meyel SWF; Netea-Maier R; van Beek AP; Neggers SJCMM
J Clin Endocrinol Metab; 2021 May; 106(6):1783-1792. PubMed ID: 33544833
[TBL] [Abstract][Full Text] [Related]
38. Acromegaly surgery in Manchester revisited--the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission.
Wang YY; Higham C; Kearney T; Davis JR; Trainer P; Gnanalingham KK
Clin Endocrinol (Oxf); 2012 Mar; 76(3):399-406. PubMed ID: 21824170
[TBL] [Abstract][Full Text] [Related]
39. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
[TBL] [Abstract][Full Text] [Related]
40. Giant growth hormone-secreting pituitary adenomas from the endocrinologist's perspective.
Koylu B; Firlatan B; Sendur SN; Oguz SH; Dagdelen S; Erbas T
Endocrine; 2023 Mar; 79(3):545-553. PubMed ID: 36318446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
